<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04077424</url>
  </required_header>
  <id_info>
    <org_study_id>single cell</org_study_id>
    <nct_id>NCT04077424</nct_id>
  </id_info>
  <brief_title>Senescent Immunity in Elders and Vaccine Responses (SILVER)</brief_title>
  <official_title>Single Cell Molecular Analysis of Influenza Vaccine Induced T Cell Responses in Adults 65 Years of Age or Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effects of age on the immune system's response to flu vaccine and to study the&#xD;
      connection between the immune system and physical and cognitive changes associated with&#xD;
      aging.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 21, 2019</start_date>
  <completion_date type="Actual">February 1, 2020</completion_date>
  <primary_completion_date type="Actual">February 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>This is an open label trial, the study nurse and participant know which of 3 FDA approved influenza vaccines are given (Fluzone-HD, FluAd, or Flublok). However the investigator and outcomes assessor are blinded to the actual vaccine given.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Hemagglutinin antigen inhibition assay titers at baseline</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemagglutinin antigen inhibition assay titers at Day 28</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Flu Vaccine</condition>
  <arm_group>
    <arm_group_label>Fluzone-High Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FDA approved high dose inactivated influenza vaccine (HD-Fluzone)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluad</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adjuvanted (MF59) inactivated influenza vaccine (Fluad)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recombinant Hemagglutinin vaccine (Flublok)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Recombinant hemagglutinin vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone-High Dose Quadrivalent</intervention_name>
    <description>Seasonal influenza vaccination with FDA approved vaccines for this age group.</description>
    <arm_group_label>Fluzone-High Dose</arm_group_label>
    <other_name>High-dose flu vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluad</intervention_name>
    <description>Adjuvanted (MF59) inactivated influenza vaccine</description>
    <arm_group_label>Fluad</arm_group_label>
    <other_name>standard-dose, inactivated influenza (flu) vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Flublock</intervention_name>
    <description>Recombinant hemagglutinin vaccine</description>
    <arm_group_label>Recombinant Hemagglutinin vaccine (Flublok)</arm_group_label>
    <other_name>Recombinant Hemagglutinin vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 65 years and over&#xD;
&#xD;
          -  Independent Living (including Assisted Living)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to understand the consent or the study.&#xD;
&#xD;
          -  Allergic to any vaccine components, excluding eggs.&#xD;
&#xD;
          -  History of Guillain-Barre.&#xD;
&#xD;
          -  Residing in a long -term care facility such as a nursing home.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>125 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Spyros Kalams</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 30, 2019</study_first_submitted>
  <study_first_submitted_qc>August 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2019</study_first_posted>
  <disposition_first_submitted>March 17, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>September 20, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 30, 2021</disposition_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Spyros Kalams</investigator_full_name>
    <investigator_title>Associate Professor Infectious Disease</investigator_title>
  </responsible_party>
  <keyword>adult 65 and older</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Hemagglutinins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All relevant findings will be published in peer-reviewed journals and data generated will be presented at national and international meetings. research articles will be deposited in the NIH National Library of Medicine's PubMed Central upon acceptance for publication.</ipd_description>
    <ipd_access_criteria>All relevant findings will be published in peer-reviewed journals and data generated will be presented at national and international meetings. Research articles will be deposited in the NIH National Library of Medicine's PubMed Central upon acceptance for publication. To the extent possible,we will make raw data available in publications (directly or online appendices). If novel techniques are developed and validated, these methods will be shared with the general scientific community in a timely fashion, and also made available via the protocols.io open access platform. As suggested by the NIH , this will be no later than the acceptance for publication of the main findings from the final data set generated within this proposal. If requests for access to data beyond that in our publications are made by members of the scientific community, we will ask that users submit requests for specific analyses, and we will strive to meet all reasonable requests.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT04077424/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT04077424/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

